{"id":203114,"date":"2018-04-04T11:49:06","date_gmt":"2018-04-04T11:49:06","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=203114"},"modified":"2018-04-04T11:49:06","modified_gmt":"2018-04-04T11:49:06","slug":"hyperuricemia-market-global-key-players-allena-pharmaceuticals-inc-astrazeneca-plccymabay-therapeutics-inc-and-jiangsu-hengrui-medicine-co-ltd-analysis-and-forecast-20172022","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hyperuricemia-market-global-key-players-allena-pharmaceuticals-inc-astrazeneca-plccymabay-therapeutics-inc-and-jiangsu-hengrui-medicine-co-ltd-analysis-and-forecast-20172022_203114.html","title":{"rendered":"Hyperuricemia Market Global Key Players- Allena Pharmaceuticals Inc, AstraZeneca Plc,CymaBay Therapeutics Inc and Jiangsu Hengrui Medicine Co Ltd Analysis and Forecast 2017-2022"},"content":{"rendered":"
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report \u201cHyperuricemia Global Clinical Trials Review, H1, 2017\u201d<\/div>\n

Hyperuricemia<\/a><\/strong><\/p>\n

Summary  <\/strong><\/p>\n

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.<\/p>\n

 Click here for sample report @ http:\/\/www.wiseguyreports.com\/sample-request\/1248529-hyperuricemia-pipeline-review-h1-2017<\/a><\/strong><\/p>\n

Report Highlights<\/strong><\/p>\n

The Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.<\/p>\n

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.<\/p>\n

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.<\/p>\n

 <\/strong><\/p>\n

Scope of the Report <\/strong><\/p>\n

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders). 
– The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities\/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
– The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects. <\/p>\n

  Table of Contents <\/strong><\/p>\n

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Hyperuricemia – Overview 
Hyperuricemia – Therapeutics Development 
Pipeline Overview 
Pipeline by Companies 
Pipeline by Universities\/Institutes 
Products under Development by Companies 
Products under Development by Universities\/Institutes 
Hyperuricemia – Therapeutics Assessment 
Assessment by Target 
Assessment by Mechanism of Action 
Assessment by Route of Administration 
Assessment by Molecule Type 
Hyperuricemia – Companies Involved in Therapeutics Development 
Allena Pharmaceuticals Inc 
AstraZeneca Plc <\/p>\n

   .Continued<\/strong><\/p>\n

For Detailed Reading Please visit @ https:\/\/www.wiseguyreports.com\/reports\/1248529-hyperuricemia-pipeline-review-h1-2017<\/a><\/strong><\/p>\n

About Us<\/strong><\/p>\n

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.<\/p>\n

 <\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report \u201cHyperuricemia Global Clinical Trials Review, H1, 2017\u201d Hyperuricemia Summary  High uric acid level, or hyperuricemia, is an excess of uric acid in blood. … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-203114","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/203114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=203114"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/203114\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=203114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=203114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=203114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}